Pipeline

Our dynamic pipeline showcases the versatility and potential of our cutting-edge platform technology. Our pipeline boasts four distinct assets, each at varying stages of development, yet all derived from the same platform. This unified approach allows us to leverage the strengths of our technology across multiple therapeutic avenues.


Program Indication Preclinical Phase 1 Phase 2 Phase 3
PRV111
Topical Cisplatin
Bio-Adhesive Patch
 Oral CIS / HGD
(Carcinoma in Situ / High-Grade Dysplasia)
PRV211
Intraoperative
Cisplatin Patch
 Head & Neck Cancers
(T1-T4, N0, M0)
PRV131
Intratumoral
Cisplatin Injectable
 Invasive Oral Cancer
(T1-T3, N0-1, M0)
Lung Cancer
(T1-T2, N0, M0)
Hydrogel
Topical
 Skin Cancer,
Actinic Keratosis
Nano Foam
& Paste
Topical
 Intra-Vesicular Treatments;
Solid Tumors
Enteric Nano
& Paste
pH-Responsive
Oral Capsules / Pills
 Oral drug delivery of
nucleotides/proteins
for GI / solid tumors
Phase 3 Active (PRV111)
Completed
Phase Initiated
Preclinical Active
Not Yet Active

Clinical Pipeline

The lead indication of the PRV System is oral cancer, followed by oral carcinoma in situ and intra-operative chemotherapy for various cancers.


Privo's Phase II clinical study on oral cancer has successfully completed meeting all of its primary and secondary endpoints. Privo oral carcinoma in situ is currently in Phase 3 development.

Current and Developing Indications

The PRV platform technology is being developed and tested for multiple cancer types, expanding treatment options for patients with various malignancies:

  • Head and Neck Cancer
  • Carcinoma in situ
  • Lung Cancer
  • Colorectal Cancer
  • Penile Cancer
  • Esophagus Cancer
  • Cervical/Vaginal/Vulvar Cancer
  • Anal Cancer
  • Ocular Squamous Cell Carcinoma
  • All Solid Tumors (PRV131)
  • Post-surgical applications